Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
British Journal of Pharmacology
|
April 19, 2005
The cardiovascular actions of anandamide: more targets?
Michael D Randall
Molecular Pharmacology
|
February 28, 2003
A new endothelial target for cannabinoids
Michael D Randall
British Journal of Clinical Pharmacology
|
February 5, 2022
Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis
Adithan Ganesh, Michael D Randall
European Journal of Pharmacology
|
December 23, 2008
Effects of hypertension on vasorelaxation to endocannabinoids in vitro
Amanda J Wheal, Michael D Randall
British Journal of Pharmacology
|
May 8, 2004
The complexities of the cardiovascular actions of cannabinoids
Michael D Randall, David A Kendall, Saoirse O'Sullivan
Vascular Pharmacology
|
April 15, 2015
Sex differences in the role of NADPH oxidases in endothelium-dependent vasorelaxation in porcine isolated coronary arteries
Pui San Wong, Michael D Randall, Richard E Roberts
European Journal of Pharmacology
|
September 13, 2003
Mechanisms of vasorelaxation to 17beta-oestradiol in rat arteries
Patcharin Tep-areenan, David A Kendall, Michael D Randall
The Journal of Pharmacology and Experimental Therapeutics
|
February 8, 2007
The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase
Saoirse E O'Sullivan, Michael D Randall, Sheila M Gardiner
European Journal of Pharmacology
|
April 26, 2012
Vasorelaxation to capsaicin and its effects on calcium influx in arteries
Jamie J Hopps, William R Dunn, Michael D Randall
British Journal of Pharmacology
|
February 11, 2004
Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)
Saoirse E O'Sullivan, David A Kendall, Michael D Randall
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
British Journal of Pharmacology
|
April 19, 2005
The cardiovascular actions of anandamide: more targets?
Michael D Randall
Molecular Pharmacology
|
February 28, 2003
A new endothelial target for cannabinoids
Michael D Randall
British Journal of Clinical Pharmacology
|
February 5, 2022
Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis
Adithan Ganesh, Michael D Randall
European Journal of Pharmacology
|
December 23, 2008
Effects of hypertension on vasorelaxation to endocannabinoids in vitro
Amanda J Wheal, Michael D Randall
British Journal of Pharmacology
|
May 8, 2004
The complexities of the cardiovascular actions of cannabinoids
Michael D Randall, David A Kendall, Saoirse O'Sullivan
Vascular Pharmacology
|
April 15, 2015
Sex differences in the role of NADPH oxidases in endothelium-dependent vasorelaxation in porcine isolated coronary arteries
Pui San Wong, Michael D Randall, Richard E Roberts
European Journal of Pharmacology
|
September 13, 2003
Mechanisms of vasorelaxation to 17beta-oestradiol in rat arteries
Patcharin Tep-areenan, David A Kendall, Michael D Randall
The Journal of Pharmacology and Experimental Therapeutics
|
February 8, 2007
The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase
Saoirse E O'Sullivan, Michael D Randall, Sheila M Gardiner
European Journal of Pharmacology
|
April 26, 2012
Vasorelaxation to capsaicin and its effects on calcium influx in arteries
Jamie J Hopps, William R Dunn, Michael D Randall
British Journal of Pharmacology
|
February 11, 2004
Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)
Saoirse E O'Sullivan, David A Kendall, Michael D Randall
Page
of 4